Early prediction of preeclampsia in high-risk women

Journal of Women's Health

Volumn 20, Issue 4, 2011, Pages 539-544

  Shaker, Olfat Gamil ^a   Shehata, Hany ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; DISEASE SEVERITY; DOPPLER FLOWMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE ARTERY; UTERINE ARTERY DOPPLER VELOCIMETRY;

ADULT; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOGISTIC MODELS; NITRIC OXIDE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PROSPECTIVE STUDIES; RHEOLOGY; ROC CURVE; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 79954456432     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2010.2378     Document Type: Article

References (37)

1. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005; 365: 785-799.
2. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long-term mortality of mothers and fathers after pre-eclampsia: Po-pulation-based cohort study. BMJ 2001;323:1213-1217
3. Fisher SJ, Roberts JM. Defects in placentation and placental perfusion. In: Lindheimer MD, Roberts JM, Cunningham FG eds. Chelsey's hypertensive disorders in pregnancy. Stam-ford, CT: Appleton & Lange, 1999: 377-394.
4. Conrad KP, Benyo DF. Placental cytokines and the patho-genesis of preeclampsia. Am J Reprod Immunol 1997;37: 240-249.
5. Maynard SE, Min JY, Merchan J, et al. Excess placental sol-uble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658. (Pubitemid 36278583)
6. Rinehart BK, Terrone DA, Lagoo-Deenadayalan S, et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol 1999;181:915-920. (Pubitemid 29503615)
7. Bdolah Y, Sukhatme VP, Karumanchi SA. Angiogenic im-balance in the pathophysiology of preeclampsia: Newer in-sights. Semin Nephrol 2004;24:548-556. (Pubitemid 39505044)
8. Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in pre-eclampsia: the "chicken-and-egg" question. Endocrinology 2004;145:4835-4837. (Pubitemid 39551099)
9. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-1085. (Pubitemid 41533005)
10. Wolf M, Shah A, Lam C, et al. Circulating levels of the an-tiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005;193:16-22. (Pubitemid 40991821)
11. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of de-veloping preeclampsia. Hypertension 2007;50:137-142. (Pubitemid 46986022)
12. Tranquilli AL, Bezzeccheri V, Giannubilo SR, Scagnoli C, Mazzanti L, Garzetti GG. Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004;113:17-20. (Pubitemid 38281188)
13. Abid M, Schoots I, Spokes K, Wu S, Mawhinney C, Aird W. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IκB/NF-κB. J Biol Chem 2004;279:44030-44038. (Pubitemid 39390712)
14. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998;59:1540-1548. (Pubitemid 28549874)
15. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-683. (Pubitemid 38364626)
16. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor re-ceptor, FLT-1, and its heterodimerization with KDR. Bio-chem Biophys Res Commun 1996;226:324-328. (Pubitemid 26331903)
17. Lu F, Longo M, Tamayo E, et al. Effect of over-expression of sFlt-1 on blood pressure and the occurrence of other mani-festations of preeclampsia in unrestrained conscious preg-nant mice. Am J Obstet Gynecol 2007;196:e1-e7.
18. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. (Pubitemid 44343543)
19. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol Regul Integr Comp Physiol 1997; 272:R441-R463.
20. Conrad KP. Animal models of pre-eclampsia: Do they exist? Fetal Med Rev 1990;2:67-88.
21. Kassab S, Miller MT, Hester R, Novak J, Granger JP. Sys-temic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. Hypertension 1998;31:315-320.
22. Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH. Second-trimester uterine artery Doppler screening in unselected populations: A review. J Matern Fetal Neonatal Med 2002;12:78-88.
23. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyro-sine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006;91:2424-2427 (Pubitemid 43855036)
24. American College of Obstetricians and Gynecologist practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159-167.
25. Bower S, Schuchter K, Campbell S. Doppler ultrasound screening as part of routine antenatal scanning: Prediction of pre-eclampsia and intrauterine growth retardation. Br J Obstet Gynaecol 1993;100:989-994. (Pubitemid 23344170)
26. Solitro M, Moore Simas T, Frost S, Rajan A, Crawford S, Maynard SE. Circulating soluble fms-like tyrosine kinase-1 (sFlt1) is increased in multiple gestation vs. singleton preg-nancies. Presented at the 39th Annual Meeting of the American Society of Nephrology, San Diego, CA, 2006.
27. Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk wo-men. Am J Obstet Gynecol 2007;197:244.e1-244.e8.
28. Espinoza J, Romero R, Nien JK, et al. Identification of pa-tients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196: 326.e1-326.e13.
29. Muller PR, James AH, Murtha PP, Yonish B, Jamison MG, Dekker G Circulating angiogenic factors and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens Pregnancy 2006;25:183-192. (Pubitemid 44655656)
30. Muy-Rivera M, Vadachkoria S, Woelk GB, Qiu C, Mahomed K, Williams MA. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res 2005;54:611-622. (Pubitemid 43161727)
31. Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of pre-eclampsia. Am J Obstet Gynecol 2004;190:1541-1547.
32. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe pre-eclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002;160:1405-1423. (Pubitemid 34411644)
33. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Hal-mesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and compli-cated pregnancies. Mol Hum Reprod 2001;7:205-210. (Pubitemid 32148349)
34. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia Am J Obstet Gynecol 2006;195:255-259. (Pubitemid 43927517)
35. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an an-tecedent of clinical preeclampsia. Am J Obstet Gynecol 2001;184:1267-1272. (Pubitemid 32434285)
36. Dikensoy E, Balat O, Pence S, Balat A, Cekmen M, Yurekli M. The changes of plasma malondialdehyde, nitric oxide and adrenomedullin levels in patients with preeclampsia. Hypertens Pregnancy 2009;28:383-389.
37. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of pre-eclampsia. Am J Obstet Gynecol 1994;171:944-948. (Pubitemid 24341474)